FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790688077> ?p ?o ?g. }

• W2790688077 abstract "102 Background: Patients with Gleason score (GS) 9-10 prostate cancer (PCa) have a high risk of early biochemical recurrence (BCR). Salvage therapy options differ depending on the upfront management strategy. Patients who received upfront surgery (RP) may be curable with salvage external beam radiation therapy (EBRT). However those who underwent EBRT or EBRT with a brachytherapy boost (EBRT+BT) are less likely to receive local salvage therapy and are commonly treated with androgen deprivation therapy (ADT). In this study, we examine the risk of distant metastases (DM) and prostate-cancer specific mortality (PCSM) among patients with GS 9-10 PCa who had BCR following RP, EBRT, or EBRT+BT. Methods: 712 patients with GS 9-10 PCa treated between 2000-2013 at 12 institutions who had BCR were included (346 RP, 282 EBRT, 84 EBRT+BT). Time to DM and PCSM were compared between groups using Cox proportional hazards models with propensity score adjustment. Propensity scores were calculated using age, T-stage, PSA, and GS. Results: In patients who had a BCR, incidence rates of DM and PCSM after RP were 40% and 28%. Rates after EBRT were 60% and 46% and after EBRT+BT were 49% and 31%. Median times to DM and PCSM were 3.5 and 4.9 years after RP, 3.7 and 5.1 years after EBRT, and 3.3 and 6.8 years after EBRT+BT. The rates of local salvage RT and systemic salvage therapy among RP patients were 38% and 59%, respectively. Local and systemic salvage rates were 5% and 31% for EBRT patients and 5% and 28% for EBRT+BT patients. EBRT patients had a shorter time interval to DM compared with RP (HR 1.4, p = .02) and EBRT+BT (HR 1.9, p < .01). EBRT patients also had a shorter time interval to PCSM compared with RP (HR 1.5, p = .02). Conclusions: Among patients with GS 9-10 PCa who experience BCR after definitive management, those treated with EBRT have a shorter time interval to DM and PCSM compared with RP and EBRT+BT. While this analysis is confounded by the differential thresholds for diagnosing a BCR after different modalities, it does suggest that outcomes following BCR after EBRT+BT and RP are similar. It also suggests that extreme dose escalation delays the onset of DM and PCSM even after BCR, when compared with conventionally-dosed EBRT alone." @default.
• W2790688077 created "2018-03-29" @default.
• W2790688077 creator A5004874300 @default.
• W2790688077 creator A5004893863 @default.
• W2790688077 creator A5008514077 @default.
• W2790688077 creator A5008857530 @default.
• W2790688077 creator A5015096941 @default.
• W2790688077 creator A5015241404 @default.
• W2790688077 creator A5015974298 @default.
• W2790688077 creator A5020281769 @default.
• W2790688077 creator A5023026845 @default.
• W2790688077 creator A5039646183 @default.
• W2790688077 creator A5044514299 @default.
• W2790688077 creator A5046657217 @default.
• W2790688077 creator A5049646055 @default.
• W2790688077 creator A5061374420 @default.
• W2790688077 creator A5066513804 @default.
• W2790688077 creator A5066698252 @default.
• W2790688077 creator A5070623757 @default.
• W2790688077 creator A5075740763 @default.
• W2790688077 creator A5076238068 @default.
• W2790688077 creator A5077141876 @default.
• W2790688077 date "2018-02-20" @default.
• W2790688077 modified "2023-09-30" @default.
• W2790688077 title "Clinical outcomes following biochemical recurrence among patients with Gleason score 9-10 prostate adenocarcinoma." @default.
• W2790688077 doi "https://doi.org/10.1200/jco.2018.36.6_suppl.102" @default.
• W2790688077 hasPublicationYear "2018" @default.
• W2790688077 type Work @default.
• W2790688077 sameAs 2790688077 @default.
• W2790688077 citedByCount "0" @default.
• W2790688077 crossrefType "journal-article" @default.
• W2790688077 hasAuthorship W2790688077A5004874300 @default.
• W2790688077 hasAuthorship W2790688077A5004893863 @default.
• W2790688077 hasAuthorship W2790688077A5008514077 @default.
• W2790688077 hasAuthorship W2790688077A5008857530 @default.
• W2790688077 hasAuthorship W2790688077A5015096941 @default.
• W2790688077 hasAuthorship W2790688077A5015241404 @default.
• W2790688077 hasAuthorship W2790688077A5015974298 @default.
• W2790688077 hasAuthorship W2790688077A5020281769 @default.
• W2790688077 hasAuthorship W2790688077A5023026845 @default.
• W2790688077 hasAuthorship W2790688077A5039646183 @default.
• W2790688077 hasAuthorship W2790688077A5044514299 @default.
• W2790688077 hasAuthorship W2790688077A5046657217 @default.
• W2790688077 hasAuthorship W2790688077A5049646055 @default.
• W2790688077 hasAuthorship W2790688077A5061374420 @default.
• W2790688077 hasAuthorship W2790688077A5066513804 @default.
• W2790688077 hasAuthorship W2790688077A5066698252 @default.
• W2790688077 hasAuthorship W2790688077A5070623757 @default.
• W2790688077 hasAuthorship W2790688077A5075740763 @default.
• W2790688077 hasAuthorship W2790688077A5076238068 @default.
• W2790688077 hasAuthorship W2790688077A5077141876 @default.
• W2790688077 hasConcept C121608353 @default.
• W2790688077 hasConcept C126322002 @default.
• W2790688077 hasConcept C126894567 @default.
• W2790688077 hasConcept C143998085 @default.
• W2790688077 hasConcept C146357865 @default.
• W2790688077 hasConcept C151730666 @default.
• W2790688077 hasConcept C17923572 @default.
• W2790688077 hasConcept C2775908122 @default.
• W2790688077 hasConcept C2776694085 @default.
• W2790688077 hasConcept C2777008409 @default.
• W2790688077 hasConcept C2777416452 @default.
• W2790688077 hasConcept C2777899217 @default.
• W2790688077 hasConcept C2779466945 @default.
• W2790688077 hasConcept C2780192828 @default.
• W2790688077 hasConcept C2780775027 @default.
• W2790688077 hasConcept C50382708 @default.
• W2790688077 hasConcept C509974204 @default.
• W2790688077 hasConcept C71924100 @default.
• W2790688077 hasConcept C86803240 @default.
• W2790688077 hasConceptScore W2790688077C121608353 @default.
• W2790688077 hasConceptScore W2790688077C126322002 @default.
• W2790688077 hasConceptScore W2790688077C126894567 @default.
• W2790688077 hasConceptScore W2790688077C143998085 @default.
• W2790688077 hasConceptScore W2790688077C146357865 @default.
• W2790688077 hasConceptScore W2790688077C151730666 @default.
• W2790688077 hasConceptScore W2790688077C17923572 @default.
• W2790688077 hasConceptScore W2790688077C2775908122 @default.
• W2790688077 hasConceptScore W2790688077C2776694085 @default.
• W2790688077 hasConceptScore W2790688077C2777008409 @default.
• W2790688077 hasConceptScore W2790688077C2777416452 @default.
• W2790688077 hasConceptScore W2790688077C2777899217 @default.
• W2790688077 hasConceptScore W2790688077C2779466945 @default.
• W2790688077 hasConceptScore W2790688077C2780192828 @default.
• W2790688077 hasConceptScore W2790688077C2780775027 @default.
• W2790688077 hasConceptScore W2790688077C50382708 @default.
• W2790688077 hasConceptScore W2790688077C509974204 @default.
• W2790688077 hasConceptScore W2790688077C71924100 @default.
• W2790688077 hasConceptScore W2790688077C86803240 @default.
• W2790688077 hasLocation W27906880771 @default.
• W2790688077 hasOpenAccess W2790688077 @default.
• W2790688077 hasPrimaryLocation W27906880771 @default.
• W2790688077 hasRelatedWork W2065094244 @default.
• W2790688077 hasRelatedWork W2067358955 @default.
• W2790688077 hasRelatedWork W2084269392 @default.
• W2790688077 hasRelatedWork W2498076434 @default.
• W2790688077 hasRelatedWork W2565455663 @default.
• W2790688077 hasRelatedWork W2603936869 @default.
• W2790688077 hasRelatedWork W2740801027 @default.
• W2790688077 hasRelatedWork W2790073478 @default.

• next